New L.B. Bohle Technology Center Advances Development of Continuous Pharmaceutical Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New L.B. Bohle Technology Center Advances Development of Continuous Pharmaceutical Processing


L.B. Bohle is constructing a technology center next to its service center in Ennigerloh, Germany to provide additional space for developing, testing, and demonstrating continuous-production process equipment for the pharmaceutical industry, the company announced in a press release. Construction started this past August, and the center is expected to open in June 2014.

“Our customers are relying more and more on continuous production,” said company founder Lorenz Bohle, in the press release. “Our technology center will aid in the development of new products that improve the continuous production process because we will be able to visualize entire production lines in one plant using material from wet and dry granulation.”

At the technology center, L.B. Bohle processing experts will work with specialists from the Universities of Dusseldorf and Graz and experts from Siemens to develop new steps for the permanent and interprocess measuring, monitoring, and controlling of the continuous production process. L.B. Bohle will use these developments to produce new equipment and optimize current machinery for use in the pharmaceutical industry.

Source: L.B. Bohle

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here